Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Tabletop particle accelerator could transform medicine and materials science 
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
